Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Gene Therapy "Trains" Immune System to Destroy Brain Cancer Cells

Study in laboratory rats, conducted at Cedars-Sinai Medical Center,
supports future translation to human trial

A new gene therapy approach that attracts and “trains” immune system cells to destroy deadly brain cancer cells also provides long-term immunity, produces no significant adverse effects and -- in the process of destroying the tumor -- promotes the return of normal brain function and behavioral skills, according to a study conducted by researchers at Cedars-Sinai Medical Center’s Board of Governors Gene Therapeutics Research Institute.

The study was conducted in a recently developed laboratory rat model of glioblastoma multiforme (GBM) that closely simulates outcomes in humans and supports the translation of this procedure to human clinical trials later this year. Results of the study are described in the Feb. 19 issue of Molecular Therapy, the journal of the American Society for Gene Therapy.

“These findings appear to be a significant milestone in creating an effective treatment for glioblastoma multiforme,” said Maria Castro, Ph.D., co-director of the Board of Governors Gene Therapeutic Research Institute and principal investigator of the study. “This therapy significantly improved survival rate, induced long-lasting systemic anti-tumor immunity, and resolved the neuropathological abnormalities caused by the tumors, which has been a stumbling block to many promising treatments.”

The article documents the gene therapy’s effectiveness in killing GBM cells and launching an effective and sustained systemic immune response. It also focuses on the safety of the therapy as well as its ability to restore normal brain function and reverse behavioral deficits caused by large tumors.

Humans with GBM often suffer behavioral abnormalities that affect concentration, memory and balance. In the animal studies, rats exhibited abnormal rotational movements. The research team found that as the tumors grew, they displaced and compressed nerve terminals and impulse-conducting axons. But long-term survivors who had received the gene therapy did not have long-term injury or behavioral impairment resulting from the tumor or the treatment.

“Tumor growth causes behavioral deficits, but even treatments, such as chemotherapy and radiation therapy, can cause learning disabilities and other cognitive problems. In our animal study, this therapy eliminated the tumor mass and reversed the deficits that were caused by the tumor,” said Pedro Lowenstein, M.D., Ph.D., co-principal investigator on the study and director of the Board of Governors Gene Therapeutics Research Institute.

Glioblastoma multiforme, the most common and deadly type of brain cancer, usually claims the lives of victims within six to 12 months of diagnosis. It is extremely difficult to treat for a variety of reasons. GBM tumors grow rapidly, often becoming large before a diagnosis is made. Also, cells readily infiltrate neighboring tissue and migrate to other areas, hampering complete surgical removal. Chemotherapy and radiation therapy are unable to eliminate all residual GBM cells, which frequently become resistant to the treatments.

The blood-brain barrier also prevents chemotherapy from effectively reaching tumor cells, and key cells needed to launch and sustain a systemic anti-tumor immune response – dendritic cells, or antigen-presenting cells – do not naturally occur within the brain.

The gene therapy approach developed at Cedars-Sinai sidesteps all of these challenges. The researchers used a virus stripped of its disease-causing genes as a vehicle to deliver two therapeutic proteins directly into the tumor cells. One protein, FMS like tyrosine kinase 3 ligand (Flt3L), drew dendritic cells into the brain. Another protein, herpes simplex virus type 1 thimidine kinase (HSV1-TK), combined with the antiviral gancyclovir (GCV), killed tumor cells.

Dendritic cells clean up debris from dying cells and in the process alert immune system cells of the existence of foreign entities, or antigens – in this case, GBM cells. Newly “educated” immune system cells then swarm to the tumor cells to destroy them.

In an earlier study, the Cedars-Sinai researchers used HSV1-TK and GCV alone to treat GBM and found that about 20 percent of the animals survived, compared to controls. By adding the dendritic-cell inducing Flt3L, the survival rate jumped to about 70 percent. Systemic immune activity was sustained, even fending off a “re-challenge” with additional tumor cells. In this study, the researchers at the BOG-GTRI reported that this therapy could also revert behavioral abnormalities caused by the growing tumor in the brain.

“In the fairly near future, this combined gene therapy may work synergistically with current therapies, including chemotherapy and radiation therapy, allowing doctors to reduce dosages and avoid side effects,” Dr. Castro said. “But with the safety, effectiveness and curative potential seen in these studies, we are hopeful that gene therapy for GBM could become the new standard of care.”

The study was supported by National Institutes of Health/National Institute of Neurological Disorders and Stroke, The Bram and Elaine Goldsmith and the Medallions Group Endowed Chairs in Gene Therapeutics, the Linda Tallen & David Paul Kane Foundation Annual Fellowship, and the Board of Governors at Cedars-Sinai.

Citation: Cancer Research, Combined immune-stimulation and conditional cytoxic gene therapy provide long term survival in a large glioma model (August 2005).

Simi Singer | Cedars-Sinai Medical Center
Further information:

Further reports about: GBM Governors Treatment behavioral immune therapeutic therapy tumor cells

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>